The Horizon Europe Candidate Partnership: One Health AMR
JPIAMR, in collaboration with other stakeholders is leading the development of the One Health AMR Partnership. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, both aimed at reducing the threat of antimicrobial resistance (AMR). The first call and launch of other activities are planned to take place in 2024.
In the research framework of Horizon Europe, the European Commission, in collaboration with the member states, has identified 49 new candidate European Partnerships of which, one of them is the “One Health AMR Partnership”. The One Health AMR (OH AMR) is a partnership co-funded by EU countries, with research funders at the core of the consortium. With a blending of EU and national public R&I funding sources (e.g. ERA-NET’s model) they will jointly elaborate on a Partnership Strategic Research and Innovation Agenda (SRIA) and implement it through joint calls and additional activities.
The OH AMR Partnership aims to coordinate and align AMR activities and funding between countries as well as with the Commission. It will also facilitate national coherence between different services and ministries with responsibility for the various aspects of AMR (e.g. human health, agriculture, environment, industry, finances).
The core group of formal members and signatories will comprise relevant ministries and funding agencies from the participating countries.
- Countries: EU Member States and Associated Countries funding agencies
- European Commission lead: DG Research and Innovation – Combating Diseases
- Initiative lead: JPIAMR – a task force based on JPIAMR member states is leading the drafting of the OH AMR Partnership proposal
Access to available, affordable and effective antimicrobial treatment is a global public good.
The One Health AMR Partnership will support research and innovation for the prevention/reduction of AMR and the development/safeguarding of effective antimicrobial treatment and interventions for human and animals.
The Strategic Research and Innovation Agenda, SRIA
The OH AMR Partnership SRIA will be based on the JPIAMR SRIA broadened to other drug-resistant pathogens including cross sectorial areas through stakeholder and expert consultations in 2021-2022.
Draft proposal process
Draft outline of partnership proposal fiche (May 2019, partnership is planned for the Work Programme 2023-2024): European Partnership for One Health/AMR Antimicrobial Resistance (AMR)
The Task Force is currently drafting a concept paper for the proposal that will be further discussed at the OH AMR Partnership policy conference on 20-21 October 2021.
2021-2022: Broadening of SRIA and definition of Partnership objectives and Roadmap of joint actions.
2023: Proposal submission to EC and collection of Members States commitments
2024: Launch of first call and start of activities
Further information and contact
To stay updated about the progress of the OH AMR Partnership please subscribe to the JPIAMR newsletter.
Contact JPIAMR: email@example.com
Contact Commission services: RTD-COMBATTING-DISEASES@ec.europa.eu